MedTrace Logo

ADVANCE-D: Antitachycardia Pacing (ATP) Delivery for Painless Implantable Cardioverter Defibrillator (ICD) Therapy

NCT00147277 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 925

Last updated 2025-07-11

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to estimate and quantify the difference in efficacy of two sequences of ATP therapies (burst 15 pulses, 88% versus burst 8 pulses, 88%) during an episode of spontaneous rhythms classified as fast ventricular tachycardia (FVT) via ventricular fibrillation (VF) in patients who have a Class I or II A indication for ICD implantation, and thus to promote the "painless" therapy aspect of ICD treatment and improve quality of life outcomes for patients.

Conditions

  • Tachycardia, Ventricular
  • Ventricular Fibrillation

Interventions

DEVICE

Implantable Cardiac Defibrillator

Medtronic Marquis Family ICD, capable of Anti Tachy Pacing (ATP) for Fast Ventricular Tachycardia (FVT) via Ventricular Fibrillation (VF) zone

Sponsors & Collaborators

  • Medtronic Cardiac Rhythm and Heart Failure

    lead INDUSTRY

Principal Investigators

  • Maurizio Lunati, Dr. · Ospedale Niguarda Cà Granda - Milano

  • Riccardo Cappato, Dr. · Istituto Policlinico S. Donato Milanese

  • Massimo Santini, Prof. · San Filippo Neri - Roma

  • Angel Arenal, Dr. · Hospital Gregorio Marañón, Madrid

  • Josè Luis Merino, Dr. · Hospital Universitario La Paz

  • Arcadio Garcia-Alberola, Dr. · Hospital Universitario Virgen de la Arrixaca

  • Johann Mermi, Dr. · Clinic Center Dortmund

  • Pascal Defaye, Dr. · University Hospital, Grenoble

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-03-31
Primary Completion
2006-01-31
Completion
2008-01-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00147277 on ClinicalTrials.gov